Home LiteratureArticle Details
PMID: 11160203 Published · ppublish English Comparative Study Journal Article Research Support, U.S. Gov't, P.H.S.

Role of phosphatidylinositol 3-kinase in anti-IgM- and anti-IgD-induced apoptosis in B cell lymphomas.

Journal of immunology (Baltimore, Md. : 1950) ·Vol. 166 ·No. 3 ·2001-02-01 ·Pages 1618-26

Carey GB, Scott DW

Abstract

Cross-linking of surface Ig receptors with anti IgM (anti-mu heavy chain, anti-mu), but not anti-IgD (anti-delta heavy chain, anti-delta), Abs leads to growth arrest and apoptosis in several extensively characterized B cell lymphomas. By poorly understood mechanisms, both Igs transiently stimulate c-Myc protein expression. However, ultimately, only anti-mu causes a severe loss in c-Myc and a large induction of p27(Kip1) protein expression. Because phosphatidylinositol 3-kinase (PI3K) has been established as a major modulator of cellular growth and survival, we investigated its role in mediating anti-Ig-stimulated outcomes. Herein, we show that PI3K pathways regulate cell cycle progression and apoptosis in the ECH408 B cell lymphoma. Anti-mu and anti-delta driven c-Myc protein changes precisely follow their effects on the PI3K effector, p70(S6K). Upstream of p70(S6K), signaling through both Ig receptors depresses PI3K pathway phospholipids below control with time, which is followed by p27(Kip1) induction. Conversely, anti-delta, but not anti-mu stimulated PI3K-dependent phospholipid return to control levels by 4-8 h. Abrogation of the PI3K pathway with specific inhibitors mimics anti-mu action, potentiates anti-mu-induced cell death and, importantly, converts anti-delta to a death signal. Transfection with active PI3K kinase construct induces anti-mu resistance, whereas transfection with dominant negative PI3K augments anti-mu sensitivity. Our results show that prolonged disengagement of PI3K or down-regulation of its products by anti-mu (and not anti-delta) determines B cell fate.

MeSH Terms
Animals Antibodies, Anti-Idiotypic/pharmacology Apoptosis/immunology Cell Cycle Proteins Chromones/pharmacology Cyclin-Dependent Kinase Inhibitor p27 Enzyme Activation/drug effects,immunology Enzyme Inhibitors/pharmacology Growth Inhibitors/pharmacology Immunoglobulin D/immunology Immunoglobulin M/immunology Immunoglobulin delta-Chains/immunology Immunoglobulin mu-Chains/immunology Lymphoma, B-Cell/enzymology,immunology,metabolism,pathology Mice Microtubule-Associated Proteins/biosynthesis,metabolism Morpholines/pharmacology Phosphatidylinositol 3-Kinases/genetics,metabolism,physiology Phosphoinositide-3 Kinase Inhibitors Proto-Oncogene Proteins c-myc/biosynthesis,metabolism Ribosomal Protein S6 Kinases/antagonists & inhibitors,metabolism Signal Transduction/immunology Transfection Tumor Cells, Cultured Tumor Suppressor Proteins
Chemicals
Antibodies, Anti-Idiotypic Cdkn1b protein, mouse Cell Cycle Proteins Chromones Enzyme Inhibitors Growth Inhibitors Immunoglobulin D Immunoglobulin M Immunoglobulin delta-Chains Immunoglobulin mu-Chains Microtubule-Associated Proteins Morpholines Phosphoinositide-3 Kinase Inhibitors Proto-Oncogene Proteins c-myc Tumor Suppressor Proteins anti-IgD anti-IgM Cyclin-Dependent Kinase Inhibitor p27 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one Ribosomal Protein S6 Kinases
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Carey G B
Department of Immunology, Holland Laboratory of the American Red Cross, Rockville, MD 20855, USA.
Scott D W
Article Info
Journal
Journal of immunology (Baltimore, Md. : 1950)
Abbr.
J Immunol
ISSN
0022-1767
Published
2001-02-01
Pages
1618-26
Language
English
Region
United States
NLM ID
2985117R
Subset
IM
Grants
NCI NIH HHS · 3R01CA55644-07S1 · United States
NCI NIH HHS · 5R01CA55644 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com